SC Japan Oncology RWDby Sumitomo Corporation
Home / Data Assets

Japan Oncology Data Assets

Two resources: EMR-derived clinical RWD and prospective clinico-genomic research data. Choose the asset by research question.

EMR RWD CLINICO-GENOMICS View Catalog View Use Cases
At a glance

Choose by research question

EMR RWD
NTT - Real World Data + Custom Curation - Cyber Oncology

Hospital registry data for treatment patterns, biomarkers, AEs, labs, and outcomes.

83,670
Catalog patients
100K
Q2 2026 target
16
Catalog sites
47
Cyber R installed sites
Read EMR RWD details
CLINICO-GENOMICS
SCRUM Japan - Multi-Study Platform - VAPORCONE

Prospective clinico-genomic data linking profiling, treatment, response, and survival.

23,000+
Registered cases
40,000
Target enrollment
20
Contributing studies
270+
SCRUM facilities
Read CLINICO-GENOMICS details
EMR RWD

Cyber Oncology: registry-based clinical oncology RWD

Cyber Oncology is built around the J-CONNECT initiative led by Kyoto University Hospital. It combines cancer registry data with medications, labs, biomarkers, reports, and targeted EMR review.

Registry baseDemographics, cancer type, diagnosis date, stage, initial treatment, survival status.
Daily EMR updatesMedication, injection, and lab data imported from hospital systems.
Report-derived fieldsBiomarker and CGP data structured from clinical reports.
Custom curationMissing fields can be supplemented through JRA-based EMR review.

J-CONNECT2 collection model

Hospital registry Medication & labs Reports & biomarkers Cyber Oncology Counts / curated datasets

What is captured

  • Patient and tumor demographics, histology, staging, metastatic sites
  • Line-of-therapy sequences, regimen, start/stop, discontinuation reason
  • Adverse events with CTCAE grading and dose modifications
  • Lab values, ECOG performance status, vitals, response, survival

Lab domains

  • Hematology, liver function, renal function, electrolytes
  • Lipid and glucose metabolism, cardiac and muscle markers
  • Pancreatic enzymes, coagulation, blood gas, specialized tests

Best fit

  • Treatment landscape and line-of-therapy sequencing
  • Patient count feasibility using clinical and biomarker criteria
  • Real-world endpoint and safety benchmarking
View EMR RWD catalog View EMR RWD use cases
CLINICO-GENOMICS

VAPORCONE: SCRUM-Japan prospective clinico-genomic platform

VAPORCONE integrates SCRUM-MONSTAR research data across clinical, genomic, biospecimen, operations, and analytics functions.

Clinical dataHistology, stage, primary site, biopsy source, treatment regimen, dates.
Genomic profileTargeted NGS, WES/WTS, ctDNA, TMB, MSI, CNV, fusions, SNV.
OutcomesORR, PFS, OS, RECIST-linked response, subject status, survival fields.
Advanced studiesSpatial omics, TME, proteomics, metabolomics, microbiome.

SCRUM-Japan platform model

270+ facilities 20 studies Multi-omics VAPORCONE

Research programs

  • LC-SCRUM-Asia and MONSTAR-SCREEN series
  • GI-SCREEN, COSMOS, GOZILA, CIRCULATE Galaxy
  • Additional solid tumor cohorts planned

Platform capabilities

  • Study operation, office, and site coordination
  • RWE views, analytics, abstraction, and extraction
  • CDISC support, SDTM conversion, ADaM-ready datasets

Best fit

  • Biomarker-defined cohort discovery and mutation prevalence
  • External control arm planning for PMDA submissions
  • Translational research and AI-ready clinico-genomic datasets
View CLINICO-GENOMICS catalog View CLINICO-GENOMICS use cases